{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54.6","spread":"54.6","upperLimit":"63.4","value":"59.0"},{"groupId":"OG001","lowerLimit":"34.1","spread":"34.1","upperLimit":"42.8","value":"38.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"478"},{"groupId":"OG001","value":"476"}],"units":"Participants"}],"description":"CBR was defined as the percentage of participants with a best overall response of CR or PR or durable SD (duration of SD \\>=23 weeks after randomization). For participants whose best overall response (BOR) was SD, the duration of SD was defined as the time from the date of randomization to the first documented PD or death, whichever occurred first. CR was defined as disappearance of any intratumoral arterial enhancement in all target lesions. PR was defined as at least a 30% decrease in the sum of diameters of viable (enhancement of arterial phase) target lesions taking as reference the baseline sum of the diameters of target lesions. SD was when a case does not qualify for either PR or PD. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the baseline sum of diameters of target lesions. As planned, data for this pre-specified endpoint was collected and analyzed up to the primary completion date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (\\>=) 60 kilogram (kg) or 8 mg based on the subject's body weight less than (\\<) 60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.","id":"OG000","title":"Lenvatinib"},{"description":"Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.","id":"OG001","title":"Sorafenib"}],"paramType":"NUMBER","populationDescription":"The FAS included all participants who were randomized.","reportingStatus":"POSTED","timeFrame":"From the date of randomization to the date of first documentation of disease progression, or date of death, whichever occurred first (approximately up to 3.8 years)","title":"Clinical Benefit Rate (CBR)","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"percentage of participants"}